Test Name
Myeloid Extended Mutation Panel
Test Code
M Myeloid Extended
Synonyms
JAK2 (V617F and Exon 12), CALR (Type 1 and 2), MPL, ASXL1, CBL, CSF3R, ETV6/TEL, EZH2, IDH1, IDH2, KIT, KRAS, NRAS, RUNX1, SETB1, SF3B1, SRSF2, TET2, TP53
Associations
Myeloproliferative neoplasms, MDS/MPN overlap disorders
CPT Codes
81450
Turnaround Time
10 days
Specimen Requirements
5.0 mL (min. 1.0 mL) whole blood EDTA preferred, heparin whole blood accepted 3.0 mL (min. 1.0 mL) bone marrow aspirate EDTA preferred, heparin accepted
Specimen Stability
EDTA whole blood or bone marrow stable at room temperature (18-25°C)
Storage & Handling
Whole blood and bone marrow ship in a Styrofoam container with a cool pack. (Do not allow cool/refrigerated pack to directly contact sample
Causes for Rejections
Insufficient DNA content; Insufficient specimen volume; Specimen at incorrect temperature; Incorrect anticoagulant
References
- Read more about Myeloproliferative Neoplasms testing by NGS here
- National Comprehensive Cancer Network. (2016). The NCCN Guidelines Myeloproliferative Neoplasms. Version 1.2017.
- Ortmann, C. A. et al. (2015). Effect of Mutation Order on Myeloproliferative Neoplasms. New England Journal of Medicine, 372(7), 601-612
- Arber et al. (2106). The 2016 revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia. Blood. 2016 May 19;127(20):2391-405
- Vainchenker W, Kralovics R. (2017) Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017 Feb 9;129(6):667-679
- Muhammad Tayyab, Z. N., & Noor, N. (2014). Distinct Gene Mutations, their Prognostic Relevance and Molecularly Targeted Therapies in Acute Myeloid Leukemia (AML). Journal of Cancer Science & Therapy, 6, 337-34
- Bejar, R. (2014). Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica, 99(6), 956-964
